Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022
Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020-March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Emerging infectious diseases - 28(2022), 11 vom: 04. Nov., Seite 2198-2205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yamayoshi, Seiya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.10.2022 Date Revised 15.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3201/eid2811.221127 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347137059 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347137059 | ||
| 003 | DE-627 | ||
| 005 | 20231226033128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3201/eid2811.221127 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1157.xml |
| 035 | |a (DE-627)NLM347137059 | ||
| 035 | |a (NLM)36198306 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yamayoshi, Seiya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2022 | ||
| 500 | |a Date Revised 15.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020-March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Japan | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a coronavirus disease | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a incidence | |
| 650 | 4 | |a respiratory infections | |
| 650 | 4 | |a seroprevalence | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a vaccine-preventable diseases | |
| 650 | 4 | |a viruses | |
| 650 | 4 | |a zoonoses | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Iwatsuki-Horimoto, Kiyoko |e verfasserin |4 aut | |
| 700 | 1 | |a Okuda, Moe |e verfasserin |4 aut | |
| 700 | 1 | |a Ujie, Michiko |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuhara, Atsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Murakami, Jurika |e verfasserin |4 aut | |
| 700 | 1 | |a Duong, Calvin |e verfasserin |4 aut | |
| 700 | 1 | |a Hamabata, Taiki |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Mutsumi |e verfasserin |4 aut | |
| 700 | 1 | |a Chiba, Shiho |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Mitamura, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hagihara, Masao |e verfasserin |4 aut | |
| 700 | 1 | |a Shibata, Akimichi |e verfasserin |4 aut | |
| 700 | 1 | |a Uwamino, Yoshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Hasegawa, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Ebina, Toshiaki |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Akihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Nakajima, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sugaya, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Seki, Yuki |e verfasserin |4 aut | |
| 700 | 1 | |a Iqbal, Asef |e verfasserin |4 aut | |
| 700 | 1 | |a Kamimaki, Isamu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamazaki, Masahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Kawaoka, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Furuse, Yuki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging infectious diseases |d 1995 |g 28(2022), 11 vom: 04. Nov., Seite 2198-2205 |w (DE-627)NLM088704254 |x 1080-6059 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:11 |g day:04 |g month:11 |g pages:2198-2205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3201/eid2811.221127 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 11 |b 04 |c 11 |h 2198-2205 | ||